Document:

prtk-ex108_658.htm

 

Exhibit 10.8

INDEMNIFICATION AGREEMENT 

This Indemnification Agreement (“Agreement”), effective as of [Date] is made by and between Paratek Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [_________________________] (“Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering the subject matter of this Agreement. 

RECITALS 

WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors or officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation; 

WHEREAS, the board of directors of the Company (the “Board”) has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities. Although the furnishing of such insurance has been a customary and widespread practice among United States-based corporations and other business enterprises, the Company believes that, given current market conditions and trends, such insurance may be available to it in the future only at higher premiums and with more exclusions. At the same time, directors, officers, and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise itself. The certificate of incorporation of the Company (the “Certificate of Incorporation”) requires indemnification of the officers and directors of the Company. Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (the “DGCL”). The Certificate of Incorporation and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification; 

WHEREAS, the uncertainties relating to such insurance and to indemnification have increased the difficulty of attracting and retaining qualified individuals; 

WHEREAS, the Board has determined that the increased difficulty in attracting and retaining qualified individuals is detrimental to the best interests of the Company and its stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future; 

WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified; 

WHEREAS, this Agreement is a supplement to and in furtherance of the Certificate of Incorporation and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; 

WHEREAS, Indemnitee does not regard the protection available under the Certificate of Incorporation and insurance as adequate in the present circumstances, and may not be willing to serve as an officer or director without adequate protection, and the Company desires Indemnitee to serve in such capacity. Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that he be so indemnified; and 

NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows: 

 

 

Section 1. Services to the Company. Indemnitee agrees to serve or to continue to serve as a director and officer of the Company. Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law), in which event the Company shall have no obligation under this Agreement to continue Indemnitee in such position. This Agreement shall not be deemed an employment contract between the Company (or any of its subsidiaries or any Enterprise) and Indemnitee. Indemnitee specifically acknowledges that Indemnitee’s employment with the Company (or any of its subsidiaries or any Enterprise), if any, is at will, and the Indemnitee may be discharged at any time for any reason, with or without cause, except as may be otherwise provided in any written employment contract between Indemnitee and the Company (or any of its subsidiaries or any Enterprise), other applicable formal severance policies duly adopted by the Board, or, with respect to service as a director or officer of the Company, by the Certificate of Incorporation, the Company’s bylaws (the “Bylaws”), and the DGCL. The foregoing notwithstanding, this Agreement shall continue in force after Indemnitee has ceased to serve as a director or officer of the Company, as provided in Section 16 hereof. 

Section 2. Definitions. As used in this Agreement: 

(a) References to “agent” shall mean any person who is or was a director, officer, or employee of the Company or a subsidiary of the Company or other person authorized by the Company to act for the Company, to include such person serving in such capacity as a director, officer, employee, fiduciary or other official of another corporation, partnership, limited liability company, joint venture, trust or other enterprise at the request of, for the convenience of, or to represent the interests of the Company or a subsidiary of the Company. 

(b) A “Change in Control” shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events: 

(i) Acquisition of Stock by Third Party. Any Person (as defined below) is or becomes the Beneficial Owner (as defined below), directly or indirectly, of securities of the Company representing 50% or more of the combined voting power of the Company’s then outstanding securities unless the change in relative Beneficial Ownership of the Company’s securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors; 

(ii) Change in Board of Directors. During any period of two (2) consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in Sections 2(b)(i), 2(b)(iii) or 2(b)(iv)) whose election by the Board or nomination for election by the Company’s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Board; 

(iii) Corporate Transactions. The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than 50% of the combined voting power of the voting securities of the surviving entity outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the board of directors or other governing body of such surviving entity; 

(iv) Liquidation. The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets; and 

(v) Other Events. There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below), whether or not the Company is then subject to such reporting requirement. 

 

 

For purposes of this Section 2(b), the following terms shall have the following meanings: 

(1) “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended from time to time. 

(2) “Person” shall have the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act; provided, however, that Person shall exclude (i) the Company, (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii) any corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company. 

(3) “Beneficial Owner” shall have the meaning given to such term in Rule 13d-3 under the Exchange Act; provided, however, that Beneficial Owner shall exclude any Person otherwise becoming a Beneficial Owner by reason of the stockholders of the Company approving a merger of the Company with another entity. 

(c) “Corporate Status” describes the status of a person who is or was a director, officer, employee or agent of the Company or of any other corporation, limited liability company, partnership or joint venture, trust or other enterprise which such person is or was serving at the request of the Company. 

(d) “Disinterested Director” shall mean a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee. 

(e) “Enterprise” shall mean the Company and any other corporation, limited liability company, partnership, joint venture, trust or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, officer, trustee, partner, managing member, employee, agent or fiduciary. 

(f) “Expenses” shall include all reasonable attorneys’ fees, retainers, court costs, transcript costs, fees of experts and other professionals, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, any federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, ERISA excise taxes and penalties, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding. Expenses also shall include (i) Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersede as bond, or other appeal bond or its equivalent, and (ii) for purposes of Section 14(d) only, Expenses incurred by Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee’s rights under this Agreement, by litigation or otherwise. The parties agree that for the purposes of any advancement of Expenses for which Indemnitee has made written demand to the Company in accordance with this Agreement, all Expenses included in such demand that are certified by affidavit of Indemnitee’s counsel as being reasonable shall be presumed conclusively to be reasonable. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee. 

(g) “Independent Counsel” shall mean a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to represent: (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning the Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement. The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto. 

(h) The term “Proceeding” shall include any threatened, pending or completed action, suit, claim, counterclaim, cross claim, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, 

 

 

administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative, legislative, or investigative (formal or informal) nature, including any appeal therefrom, in which Indemnitee was, is or will be involved as a party, potential party, non-party witness or otherwise by reason of the fact that Indemnitee is or was a director or officer of the Company, by reason of any action taken by him (or a failure to take action by him) or of any action (or failure to act) on his part while acting pursuant to his Corporate Status, in each case whether or not serving in such capacity at the time any liability or Expense is incurred for which indemnification, reimbursement, or advancement of Expenses can be provided under this Agreement. If the Indemnitee believes in good faith that a given situation may lead to or culminate in the institution of a Proceeding, this shall be considered a Proceeding under this paragraph. 

(i) Reference to “other enterprise” shall include employee benefit plans; references to “fines” shall include any excise tax assessed with respect to any employee benefit plan; references to “serving at the request of the Company” shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner he reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in manner “not opposed to the best interests of the Company” as referred to in this Agreement. 

Section 3. Indemnity in Third-Party Proceedings. The Company shall indemnify Indemnitee in accordance with the provisions of this Section 3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 3, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses, judgments, fines and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines and amounts paid in settlement) actually and reasonably incurred by Indemnitee or on his behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal Proceeding had no reasonable cause to believe that his conduct was unlawful. The parties hereto intend that this Agreement shall provide to the fullest extent permitted by law for indemnification in excess of that expressly permitted by statute, including, without limitation, any indemnification provided by the Certificate of Incorporation, the Bylaws, vote of its stockholders or disinterested directors or applicable law. 

Section 4. Indemnity in Proceedings by or in the Right of the Company. The Company shall indemnify Indemnitee in accordance with the provisions of this Section 4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 4, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses actually and reasonably incurred by him or on his behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this Section 4 in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that the Delaware Court or any court in which the Proceeding was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification. 

Section 5. Indemnification for Expenses of a Party Who is Wholly or Partly Successful. Notwithstanding any other provisions of this Agreement, to the fullest extent permitted by applicable law and to the extent that Indemnitee is a party to (or a participant in) and is successful, on the merits or otherwise, in any Proceeding or in defense of any claim, issue or matter therein, in whole or in part, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or on his behalf in connection with or related to each successfully resolved claim, issue or matter to the fullest extent permitted by law. For purposes of this Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter. 

 

 

Section 6. Indemnification For Expenses of a Witness. Notwithstanding any other provision of this Agreement, to the fullest extent permitted by applicable law and to the extent that Indemnitee is, by reason of his Corporate Status, a witness or otherwise asked to participate in any Proceeding to which Indemnitee is not a party, he shall be indemnified against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith. 

Section 7. Partial Indemnification. If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of Expenses, but not, however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled. 

Section 8. Additional Indemnification. 

(a) Notwithstanding any limitation in Section 3, Section 4, or Section 5, the Company shall indemnify Indemnitee to the fullest extent permitted by applicable law if Indemnitee is a party to or threatened to be made a party to any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines and amounts paid in settlement) actually and reasonably incurred by Indemnitee in connection with the Proceeding. 

(b) For purposes of Section 8(a), the meaning of the phrase “to the fullest extent permitted by applicable law” shall include, but not be limited to: 

(i) to the fullest extent permitted by the provision of the DGCL that authorizes or contemplates additional indemnification by agreement, or the corresponding provision of any amendment to or replacement of the DGCL, and 

(ii) to the fullest extent authorized or permitted by any amendments to or replacements of the DGCL adopted after the date of this Agreement that increase the extent to which a corporation may indemnify its officers and directors. 

Section 9. Exclusions. Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnification payment in connection with any claim made against Indemnitee: 

(a) for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision; or 

(b) for (i) an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Exchange Act (as defined in Section 2(b) hereof) or similar provisions of state statutory law or common law, or (ii) any reimbursement of the Company by the Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by the Indemnitee from the sale of securities of the Company, as required in each case under the Exchange Act (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 306 of the Sarbanes-Oxley Act); or 

(c) except as provided in Section 14(d) of this Agreement, in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law. 

Section 10. Advances of Expenses. Notwithstanding any provision of this Agreement to the contrary (other than Section 14(d)), the Company shall advance, to the extent not prohibited by law, the Expenses incurred by 

 

 

Indemnitee in connection with any Proceeding (or any part of any Proceeding) not initiated by Indemnitee, and such advancement shall be made within thirty (30) days after the receipt by the Company of a statement or statements requesting such advances from time to time, whether prior to or after final disposition of any Proceeding. Advances shall be unsecured and interest free. Advances shall be made without regard to Indemnitee’s ability to repay the Expenses and without regard to Indemnitee’s ultimate entitlement to indemnification under the other provisions of this Agreement. In accordance with Section 14(d), advances shall include any and all reasonable Expenses incurred pursuing an action to enforce this right of advancement, including Expenses incurred preparing and forwarding statements to the Company to support the advances claimed. The Indemnitee shall qualify for advances upon the execution and delivery to the Company of this Agreement, which shall constitute an undertaking providing that the Indemnitee undertakes to repay the amounts advanced (without interest) to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company. No other form of undertaking shall be required other than the execution of this Agreement. This Section 10 shall not apply to any claim made by Indemnitee for which indemnity is excluded pursuant to Section 9. 

Section 11. Procedure for Notification and Defense of Claim. 

(a) Indemnitee shall notify the Company in writing of any matter with respect to which Indemnitee intends to seek indemnification or advancement of Expenses hereunder as soon as reasonably practicable following the receipt by Indemnitee of written notice thereof. The written notification to the Company shall include a description of the nature of the Proceeding and the facts underlying the Proceeding. To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification following the final disposition of such Proceeding. The omission by Indemnitee to notify the Company hereunder will not relieve the Company from any liability which it may have to Indemnitee hereunder or otherwise than under this Agreement, and any delay in so notifying the Company shall not constitute a waiver by Indemnitee of any rights under this Agreement. The Secretary of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification. 

(b) The Company will be entitled to participate in the Proceeding at its own expense. 

Section 12. Procedure Upon Application for Indemnification. 

(a) Upon written request by Indemnitee for indemnification pursuant to Section 11(a), a determination, if required by applicable law, with respect to Indemnitee’s entitlement thereto shall be made in the specific case: (i) if a Change in Control shall have occurred, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee; or (ii) if a Change in Control shall not have occurred, (A) by a majority vote of the Disinterested Directors, even though less than a quorum of the Board, (B) by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum of the Board, (C) if there are no such Disinterested Directors or, if such Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee or (D) if so directed by the Board, by the stockholders of the Company; and, if it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten (10) days after such determination. Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or Expenses (including attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee’s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom. The Company promptly will advise Indemnitee in writing with respect to any determination that Indemnitee is or is not entitled to indemnification, including a description of any reason or basis for which indemnification has been denied. 

(b) In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 12(a) hereof, the Independent Counsel shall be selected as provided in this 

 

 

Section 12(b). If a Change in Control shall not have occurred, the Independent Counsel shall be selected by the Board, and the Company shall give written notice to Indemnitee advising him of the identity of the Independent Counsel so selected. If a Change in Control shall have occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board, in which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either event, Indemnitee or the Company, as the case may be, may, within ten (10) days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel” as defined in Section 2 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or the Delaware Court has determined that such objection is without merit. If, within twenty (20) days after the later of submission by Indemnitee of a written request for indemnification pursuant to Section 11(a) hereof and the final disposition of the Proceeding, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition the Delaware Court for resolution of any objection which shall have been made by the Company or Indemnitee to the other’s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by such court or by such other person as such court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section 12(a) hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 14(a) of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing). 

Section 13. Presumptions and Effect of Certain Proceedings. 

(a) In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination shall, to the fullest extent not prohibited by law, presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 11(a) of this Agreement, and the Company shall, to the fullest extent not prohibited by law, have the burden of proof to overcome that presumption in connection with the making by any person, persons or entity of any determination contrary to that presumption. Neither the failure of the Company (including by its directors or Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or Independent Counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct. 

(b) Subject to Section 14(e), if the person, persons or entity empowered or selected under Section 12 of this Agreement to determine whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification shall, to the fullest extent not prohibited by law, be deemed to have been made and Indemnitee shall be entitled to such indemnification, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law; provided, however, that such 60-day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making the determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and/or information relating thereto; and provided, further, that the foregoing provisions of this Section 13(b) shall not apply (i) if the determination of entitlement to indemnification is to be made by the stockholders pursuant to Section 12(a) of this Agreement and if (A) within fifteen (15) days after receipt by the Company of the request for such determination the Board has resolved to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within seventy-five (75) days after such receipt and such determination is made thereat, or (B) a special meeting of stockholders is called within fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose within sixty (60) days after having been so called and such 

 

 

determination is made thereat, or (ii) if the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 12(a) of this Agreement. 

(c) The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his conduct was unlawful. 

(d) For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee’s action is based on the records or books of account of the Enterprise, including financial statements, or on information supplied to Indemnitee by the directors or officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise or on information or records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser or other expert selected with the reasonable care by the Enterprise. The provisions of this Section 13(d) shall not be deemed to be exclusive or to limit in any way the other circumstances in which the Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement. 

(e) The knowledge and/or actions, or failure to act, of any director, officer, trustee, partner, managing member, fiduciary, agent or employee of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement. 

Section 14. Remedies of Indemnitee. 

(a) Subject to Section 14(e), in the event that (i) a determination is made pursuant to Section 12 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 10 of this Agreement, (iii) no determination of entitlement to indemnification shall have been made pursuant to Section 12(a) of this Agreement within ninety (90) days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to Section 5, Section 6 or Section 7 or the last sentence of Section 12(a) of this Agreement within ten (10) days after receipt by the Company of a written request therefor, (v) payment of indemnification pursuant to Section 3, Section 4 or Section 8 of this Agreement is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification, or (vi) in the event that the Company or any other person takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes any litigation or other action or Proceeding designed to deny, or to recover from, the Indemnitee the benefits provided or intended to be provided to the Indemnitee hereunder, Indemnitee shall be entitled to an adjudication by a court of his entitlement to such indemnification or advancement of Expenses. Alternatively, Indemnitee, at his option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 14(a); provided, however, that the foregoing clause shall not apply in respect of a proceeding brought by Indemnitee to enforce his rights under Section 5 of this Agreement. The Company shall not oppose Indemnitee’s right to seek any such adjudication or award in arbitration. 

(b) In the event that a determination shall have been made pursuant to Section 12(a) of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 14 shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Section 14 the Company shall have the burden of proving Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be. 

(c) If a determination shall have been made pursuant to Section 12(a) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 14, absent (i) a misstatement by Indemnitee of a material fact, or an 

 

 

omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law. 

(d) The Company shall, to the fullest extent not prohibited by law, be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 14 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement. It is the intent of the Company that, to the fullest extent permitted by law, the Indemnitee not be required to incur legal fees or other Expenses associated with the interpretation, enforcement or defense of Indemnitee’s rights under this Agreement by litigation or otherwise because the cost and expense thereof would substantially detract from the benefits intended to be extended to the Indemnitee hereunder. The Company shall, to the fullest extent permitted by law, indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee, shall (within ten (10) days after receipt by the Company of a written request therefor) advance, to the extent not prohibited by law, such Expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advance of Expenses from the Company under this Agreement or under any directors’ and officers’ liability insurance policies maintained by the Company if, in the case of indemnification, Indemnitee is wholly successful on the underlying claims; if Indemnitee is not wholly successful on the underlying claims, then such indemnification shall be only to the extent Indemnitee is successful on such underlying claims or otherwise as permitted by law, whichever is greater. 

(e) Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement of Indemnitee to indemnification under this Agreement shall be required to be made prior to the final disposition of the Proceeding. 

Section 15. Non-Exclusivity; Survival of Rights; Insurance; Subrogation. 

(a) The rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation, the Bylaws, any agreement, a vote of stockholders or a resolution of directors, or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the Certificate of Incorporation and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy. 

(b) To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees, or agents of the Enterprise, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, officer, employee or agent under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of such claim or of the commencement of a Proceeding, as the case may be, to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies. 

(c) In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights. 

 

 

(d) The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable (or for which advancement is provided hereunder) hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise. 

Section 16. Duration of Agreement. This Agreement shall continue until and terminate upon the later of: (a) ten (10) years after the date that Indemnitee shall have ceased to serve as a director or officer of the Company or (b) one (1) year after the final termination of any Proceeding then pending in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any proceeding commenced by Indemnitee pursuant to Section 14 of this Agreement relating thereto. The indemnification and advancement of expenses rights provided by or granted pursuant to this Agreement shall be binding upon and be enforceable by the parties hereto and their respective successors and assigns (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), shall continue as to an Indemnitee who has ceased to be a director, officer, employee or agent of the Company or of any other Enterprise, and shall inure to the benefit of Indemnitee and his or her spouse, assigns, heirs, devisees, executors and administrators and other legal representatives. 

Section 17. Severability. If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby. 

Section 18. Enforcement. 

(a) The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve or to continue to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director or officer of the Company. 

(b) This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof; provided, however, that this Agreement is a supplement to and in furtherance of the Certificate of Incorporation and applicable law, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder. 

Section 19. Modification and Waiver. No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver. 

Section 20. Notice by Indemnitee. Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement of Expenses covered hereunder. The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have to the Indemnitee under this Agreement or otherwise. 

 

 

Section 21. Notices. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given if (a) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (b) mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed, (c) mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been directed or (d) sent by facsimile transmission, with receipt of oral confirmation that such transmission has been received: 

(a) If to Indemnitee, at the address indicated on the signature page of this Agreement, or such other address as Indemnitee shall provide to the Company. 

	
 
	
(b)
	
If to the Company to 

Paratek Pharmaceuticals, Inc. 

75 Park Plaza, 4th Floor

Boston, MA 02116

or to any other address as may have been furnished to Indemnitee by the Company. 

Section 22. Contribution. To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i) the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such Proceeding; and/or (ii) the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and/or transaction(s). 

Section 23. Applicable Law and Consent to Jurisdiction. This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section 14(a) of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Chancery Court of the State of Delaware (the “Delaware Court”), and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) appoint, to the extent such party is not otherwise subject to service of process in the State of Delaware, irrevocably The Corporation Trust Company, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801 as its agent in the State of Delaware as such party’s agent for acceptance of legal process in connection with any such action or proceeding against such party with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum. 

Section 24. Identical Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement. 

Section 25. Miscellaneous. Use of the masculine pronoun shall be deemed to include usage of the feminine pronoun where appropriate. The headings of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof. 

 

 

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the [day] of [month], [year]. 

 

	
PARATEK PHARMACEUTICALS, INC.
	
 
	
INDEMNITEE

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
By:
	
 
	
 
	
 
	
By:
	
 
	
 

	
Name:
	
 
	
 
	
 
	
Name:
	
 
	
 

	
Title:
	
 
	
 
	
 
	
Address:EX-10.6

 Exhibit 10.6 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

AMENDED AND RESTATED MANUFACTURING AND SUPPLY AGREEMENT 

THIS AMENDED AND RESTATED MANUFACTURING AND SUPPLY AGREEMENT (this “Agreement”) is entered into by and between
Fresenius Kabi Deutschland GmbH, a company organized under the laws of Germany (together with its affiliates “Fresenius Kabi”), and CERUS CORPORATION, a company organized under the
laws of Delaware (“Cerus”). Fresenius Kabi and Cerus are sometimes referred to herein as a “Party” and collectively as the “Parties.” This Agreement shall be effective as of July 1, 2015 (the
“Effective Date”). 
 WHEREAS, Cerus and Fresenius Kabi have been parties to an agreement, as had been amended and
restated several times, most recently on December 12, 2008 and November 22, 2013 (the “Original Supply Agreement”) relating to the INTERCEPT Blood System; 

WHEREAS, Cerus desires to ensure continuity of supply and achieve acceptable cost of goods regarding the supply of Manufactured
Products, as such term is defined in this Agreement; 
 WHEREAS, Fresenius Kabi desires to supply Cerus with its requirements for
Manufactured Products; and 
 WHEREAS, the Parties now wish to further amend and restate the Original Supply Agreement in the manner
set forth in this Agreement; 
 NOW, THEREFORE, in consideration of the premises and covenants set forth herein and other good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Fresenius Kabi and Cerus agree as follows: 
 Article
1 
 Definitions 
 In this Agreement,
the following terms have the meanings specified or referred to in this Article 1 and shall be equally applicable to both the singular and plural forms. The words “including”, “includes” and “include” shall be deemed to
be followed by the phrase “without limitation”, unless the context clearly dictates otherwise. Any agreement, schedule, attachment or exhibit referred to herein shall mean such agreement, schedule, attachment or exhibit as amended,
restated, supplemented or modified from time to time to the extent permitted by the applicable provisions of this Agreement. Reference to any statute or regulation means such statute or regulation as amended at the time and from time to time and
includes any successor statute or regulation. Unless otherwise stated, references to recitals, articles, sections, paragraphs, schedules and exhibits shall be references to recitals, articles, sections, paragraphs, schedules and exhibits of this
Agreement. 
 “AAA” shall have the meaning ascribed to it in Section 12.12. 

“Affiliate” means, with respect to any Person, at the time in question, any other Person 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 

  
 1 

 
controlling, controlled by or under common control with such Person. For purposes of this definition, “control” shall mean (a) in the case of corporate entities, direct or indirect
ownership of any of the stock or shares having the right to vote for the election of a majority of directors, (b) in the case of non-corporate entities, direct or indirect ownership of any of the equity interest with the power to direct the
management and policies of such non-corporate entities. 
 [ * ] 

“APAC Countries” means the following countries: Afghanistan, American Samoa, Australia, Bangladesh, Bhutan, Brunei, Cambodia, China, Cook
Islands, East Timor, Federated States of Micronesia, Fiji, French Polynesia, Guam, Hong Kong, India, Indonesia, Japan, Kiribati, Laos, Macau, Malaysia, Maldives, Marshall Islands, Mongolia, Myanmar, Nauru, Nepal, New Caledonia, New Zealand, Niue,
North Korea, Northern Mariana Islands, Pakistan, Palau, Papua New Guinea, Philippines, Samoa, Singapore, Solomon Islands, South Korea, Sri Lanka, Taiwan, Thailand, Timor-Leste, Tokelau, Tonga, Tuvalu, Vanuatu, Vietnam, Wallis and Futuna. 

“Breach” shall have the meaning ascribed to it in Section 11.3(a). 

“Business Continuity Plan” shall have the meaning ascribed to it in Section 2.1(c). 

“Business Heads” shall have the meaning ascribed to it in Section 4.3(c). 

“Cerus Assets” shall have the meaning ascribed to it in Section 4.3(e). 

“Cerus Discounted Transfer Price” shall have the meaning ascribed to it in Section 4.1(b). 

“Cerus Indemnified Parties” shall have the meaning ascribed to it in Section 11.1(a). 

“Cerus-Supplied Materials” shall have the meaning ascribed to it in Section 5.1(a). 

“Cerus Transfer Price” shall have the meaning ascribed to it in Section 4.1(a). 

“Components” means all raw materials and sub-assemblies, such as plastics, containers (including without limitation “wet-filled”
containers), tubing, cannulas and compound adsorption devices and Intersol Solution for the production of or use in connection with the Sets and RBC Sets. 

“Confidential Information” shall have the meaning ascribed to it in Section 10.1. 

“Conversion Loss Reduction Plan” shall have the meaning ascribed to it in Section 4.2(b). 

“Cost of Goods” means Fresenius Kabi’s fully burdened cost of manufacturing a New Product and shall be equal to the sum of the following
costs to the extent reasonably and properly allocable to such New Product, in each case calculated in accordance with accounting principles 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 2 

 
generally accepted in the United States, consistently applied, (GAAP): [ * ]; provided, for purposes of clarification, that the allocation of the foregoing costs shall be made to generally
reflect [ * ] and will not include [ * ]. Delivery costs, insurance, freight, import and export duties and taxes are not included in Cost of Goods. 

“Current Good Manufacturing Practice” or “cGMP” means the then-current standards for the manufacture of pharmaceutical
products, as applicable pursuant to (a) the FD&C Act (21 U.S.C. 321 et seq.); (b) relevant United States regulations in Title 21 of the United States Code of Federal Regulations (including Parts 11, 210, and 211); (c) EC Directive
2003/94 EC of October 8, 2003; (d) the EC Guide to Good Manufacturing Practice for Medicinal Intermediate Products; (e) International Conference on Harmonization (ICH) ICH Q7A Good Manufacturing Practice Guidance for Active
Pharmaceutical Ingredients; (f) any Japanese laws, rules, guidelines, or regulations corresponding to the subject matter of the foregoing; and (g) all additional Regulatory Authority documents or regulations that replace, amend, modify,
supplant or complement any of the foregoing 
 “Current Pricing Term” means the period commencing with the Effective Date and ending on [ *
]. 
 “Damages” shall have the meaning ascribed to it in Section 11.3(b). 

“Device Master Record” shall include device specifications, production process specifications, quality assurance procedures and
specifications (including acceptance criteria and quality assurance equipment to be used), and packaging and labeling specifications. 

“Documentation” shall have the meaning ascribed to it in Section 5.3(b). 

“Facility” shall have the meaning ascribed to it in Section 2.2(c). 

“Force Majeure Event” shall have the meaning ascribed to it in Section 12.5. 

“Fresenius Kabi Elements” shall have the meaning ascribed to it in Section 11.1(a). 

“Fresenius Kabi Indemnified Parties” shall have the meaning ascribed to it in Section 11.1(c). 

“Funded Development Costs” shall have the meaning ascribed to it in Section 6.1(c). 

“Funded Projects” means the projects set forth on Exhibit D. 

“Future Products” shall have the meaning ascribed to it in Section 6.2. 

“GSH” shall mean glutathione sodium salt, a tripeptide used to quench S-303 side reactions. 

“IFUs” shall have the meaning ascribed to it in Section 4.2(b). 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 3 

 “Indemnifying Parties” shall have the meaning ascribed to it in Section 11.2(a). 

“Initial Term” shall have the meaning ascribed to it in Section 7.1(a). 

“INTERCEPT Illuminator” means a proprietary illumination device, including operating software and data management system, including
source code for each, developed for use with Platelet Sets and Plasma Sets. 
 “Intersol Solution” means a proprietary platelet
storage solution currently sold under the trademark “Intersol.” 
 “Liabilities” shall have the meaning ascribed to it in
Section 11.3(c). 
 “License Agreement” means the agreement entered between Fresenius Kabi (as successor-in interest to Baxter)
and Cerus, effective February 2, 2005, governing the ownership of and licensed rights to certain patents, know-how and materials. 

“Licensed Assets” means the Licensed Know-How, Licensed Materials and Licensed Patents, in each case as defined and set forth in the
License Agreement. 
 “Manufactured Products” means Platelet Sets, Plasma Sets, RBC Sets, Components and any New Products. 

“Manufacturing Services” shall have the meaning ascribed to it in Section 2.1(a). 

“Negotiation Period” shall have the meaning ascribed to it in Section 4.1(e). 

“New Pricing Term” means the Remainder Term and any Renewal Period for which the Parties must negotiate the applicable Transfer Price. 

“New Products” means any Future Products or new products resulting from the Funded Projects. 

“New Transfer Price” shall have the meaning ascribed to it in Section 4.1(c). 

“Permitted Assignees” shall have the meaning ascribed to it in Section 12.2(a). 

“Person” means an individual, corporation, limited liability company, partnership, sole proprietorship, joint venture, or other form of
organization or governmental agency or authority. 
 “Phase 4 Project” means each of the designated Funded Projects set forth on Exhibit
F under the title “Phase 4 Projects.” 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 4 

 “Phase 4 Project Milestone” means the date on which annual production volume of Sets and RBC
Sets is [ * ]. 
 “Plasma Disks” means sintered porous plastic adsorbent disks designed for the pathogen inactivation system for plasma.

 “Plasma Sets” means disposable processing sets for inactivation of pathogens in plasma components of blood, containing S-59. 

“Platelet Sets” means disposable processing sets for the inactivation of pathogens in platelet components of blood, containing S-59. 

“Platelet Wafers” means sintered porous plastic adsorbent wafers designed for the pathogen inactivation system for platelets. 

“Proceedings” shall have the meaning ascribed to it in Section 11.3(d). 

“Product Specifications” means the specifications for the Platelet Sets, the Plasma Sets and RBC Sets (as described in Section 2.1(b)),
and as modified from time to time pursuant to Section 2.2 and Article 6. The Product Specifications for Components will be the applicable specifications for Components included within the Product Specifications mentioned above in this
definition, or if such do not exist for any Component, then specifications to be developed by the Parties for such Component. 
 “PPI”
shall have the meaning ascribed to it in Section 4.1(e). 
 “Quality Agreement” means that certain quality agreement dated
2 April 2012 and amended as of 7 April 2014, which agreement shall be amended and restated by the parties no later than November 30, 2015. Upon execution, “Quality Agreement” shall thereafter mean such amended and restated
quality agreement. 
 “QSRs” shall have the meaning ascribed to it in Section 2.2(d). 

“RBC Filter Set” means a disposable set for the sterile delivery of red blood cells, GSH and S-303 for the pathogen inactivation system for
red blood cells. 
 “RBC Processing Set” means a disposable set for the mixing, incubation and storage of red blood cells for the pathogen
inactivation system for red blood cells. 
 “RBC Sets” means disposable processing sets for the inactivation of pathogens in red blood cell
components of blood, containing GSH, S-303, an RBC Filter Set and an RBC Processing Set. 
 “Regulatory Approval” means, for a particular
country or regulatory jurisdiction, all approvals 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 5 

 
from the applicable Regulatory Authority required for the commercial marketing or sales of the Manufactured Products in such country, along with satisfaction of any related applicable regulatory
requirements 
 “Regulatory Authority” means any regulatory authority or entity having the responsibility, jurisdiction, and authority to
approve or regulate the manufacture, use, importation, packaging, labeling, marketing and sale of the Manufactured Products in any country or regulatory jurisdiction, including without limitation the United States and the European Union. 

“Remainder Term” shall have the meaning ascribed to it in Section 4.1(d). 

“Renewal Term” shall have the meaning ascribed to it in Section 7.1(a). 

“S-303” shall mean the raw material S-303:2HCL powder used for the inactivation of pathogens. 

“S-59” means the raw material amotosalen HCl, a component of Platelet Sets and Plasma Sets. 

“Second Facility” shall have the meaning ascribed to it in Section 2.2(c). 

“Sets” means the Platelet Sets and the Plasma Sets. 

“Steering Committee” shall have the meaning ascribed to it in Section 4.3. 

“Supply Disruption” means any event the consequence of which is Fresenius Kabi is unable to fulfill Cerus’ reasonable purchase orders
for a period in excess of [ * ] days, except to the extent that such disruption is due to Cerus’ failure to deliver any Cerus-Supplied Material that is required for the manufacture of the applicable Manufactured Product. 

“Term” shall have the meaning ascribed to it in Section 7.1(a). 

“Territory” means all countries in the world, except the APAC Countries or elsewhere where local or regional manufacturing is needed to
obtain product registrations or sales. 
 “Third Party Changes” shall have the meaning ascribed to it in Section 2.2(a). 

“Transfer Price” shall have the meaning ascribed to it in Section 4.1(a). 

“Unfunded Projects” shall have the meaning ascribed to it in Section 4.4(b). 

“Warranty Period” shall have the meaning ascribed to it in Section 3.1(e). 

“Work Order” means a written, signed order for the performance by Fresenius Kabi of mutually-agreed services. A Work Order shall include a
scope of work, a project budget and a payment schedule. All Work Orders shall be deemed to be incorporated into this Agreement and governed by its terms and conditions. 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 6 

 Article 2 

Manufacturing and Supply 

Section 2.1 Manufacturing Services. 

(a) General. Fresenius Kabi will, during the term of this Agreement, manufacture Manufactured Products for Cerus on the terms set forth
below all in accordance with the Product Specifications (collectively, the “Manufacturing Services”) in a professional and efficient manner and in accordance with the terms and conditions of this Agreement and the Quality Agreement.

 (b) Product Specifications for Platelet and Plasma Sets. As of the Effective Date, the Product Specifications for the Platelet
Sets and Plasma Sets are listed on Exhibit A and Exhibit B, respectively, to this Agreement. The Product Specification for the RBC Sets shall be subsequently added by amendment hereto and set forth on Exhibit C. 

(c) Business Continuity Plan. On or prior to December 1st of each calendar
year during the Term, Fresenius Kabi shall provide Cerus with a report on manufacturing capacity at the Facility for the following [ * ] based on the “optimistic” and “base case” forecasts provided by Cerus pursuant to
Section 2.4, and a business continuity plan setting forth its ability to provide Manufactured Products during the remainder of the Term (collectively, the “Business Continuity Plan”). The Business Continuity Plan effective as
of the Effective Date has been provided to Cerus concurrently herewith. 
 Section 2.2 Change Requests. 

(a) Product Specifications; Device Master Record. In the event that Cerus requests any changes to a Product Specification (including,
without limitation, the addition of new product codes or changes made to comply with any requirement, order or instructions by any Regulatory Authority), Fresenius Kabi will perform and complete such requests in a timely fashion. Fresenius Kabi will
not unreasonably withhold or delay its approval to any requests of Cerus to change Product Specifications. Any changes to the Product Specifications or Device Master Record must be reviewed and approved under Fresenius Kabi and/or Cerus change
control procedures. Fresenius Kabi will make no changes to the Device Master Record for the Manufactured Products without the prior written approval of Cerus. The parties acknowledge certain changes are caused by third-party suppliers
(“Third Party Changes) and are thus outside the scope of Fresenius Kabi’s control. Fresenius Kabi shall give Cerus at least [ * ] days’ notice of any such Third Party Changes, provided such third party gave sufficient notice to
Fresenius Kabi. If, due to circumstances beyond Fresenius Kabi’s control, Fresenius Kabi is required to qualify a new third-party supplier, it will so notify Cerus and the Parties will confer on the determination of and terms of agreement with
such new third-party supplier. Except for such changes as may be contemplated by the Funded Projects set forth on Exhibit F, the terms of which are governed by Section 6.1, allocation of costs for such changes is further described in
Section 4.4(a). 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 7 

 (b) Product Development; Product Improvements; Prototypes. Periodically, Cerus may request
that Fresenius Kabi manufacture prototype development or clinical lots, or request additional validation or qualification activities to obtain Regulatory Approval. Fresenius Kabi will manufacture and supply prototype or clinical lots of the
Manufactured Products, as Cerus may reasonably require in connection with any changes to Product Specifications. Subject to Article 6, allocation of costs for such changes shall be allocated in accordance with Section 4.4(b). 

(c) Changes in Manufacturing Location. The Fresenius Kabi facility in La Châtre, France shall be the primary manufacturing site
and product development support center for the Manufactured Products (the “Facility”). Fresenius Kabi will not make any change in its manufacturing location without Cerus’ prior written consent, which consent will not be
unreasonably withheld or delayed, and, in any event, will not change any location until the new location is fully-qualified and licensed with each applicable Party’s regulatory group for the manufacture of the Manufactured Products for sale or
clinical testing. Changes in manufacturing location include changes in manufacturing location for raw materials, components, subassemblies, or finished goods; changes in location or subcontractor for sterilization processes; and changes in chemical
and physical facilities. In the event that annual production volumes for a Manufactured Product reach [ * ] or more of the maximum annual production capacity for the Facility, as set forth in the Business Continuity Plan Fresenius Kabi shall
identify and qualify a second Fresenius Kabi facility with ISO 13485 certification and an FDA establishment license for the manufacture of the applicable Manufactured Product, which second facility shall have low overhead and labor costs associated
with the manufacture of goods (the “Second Facility”). The transfer pricing for Manufactured Products manufactured at such Second Facility shall be subject to mutual agreement by the Parties based on good faith discussions, taking
into account Fresenius Kabi’s costs and cost savings, the effects of any efficiencies realized as a result, any amortization of capital equipment costs incurred and contemplated by Section 4.4(c) hereof, and such other factors as may be
reasonably relevant; provided, however, in no event shall such prices exceed those as set forth on Exhibit D-1. Allocation of costs for any such changes is further described in Section 4.4(c). 

(d) U.S. FDA Compliance. Upon Cerus’ written request, Fresenius Kabi agrees to review and modify, as may be necessary, and
maintain its existing manufacturing facilities and quality systems to be compliant with FDA quality system requirements (“QSRs”) and cGMP. In the event of a modification to meet QSRs, cGMP and standards applicable to the United
States, Europe or APAC Countries (if applicable), Fresenius Kabi will review and modify its existing manufacturing facilities in agreement with Cerus. Allocation of costs for such changes is further described in Section 4.4(d). 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 8 

 (e) Plastics. Cerus understands that Fresenius Kabi may receive, from time-to-time,
“Supplier Notice of Change” notifications from Baxter for any of the formulations for the key plastics used in the Platelet and Plasma Sets manufactured by Baxter. No such changes, however, shall cause the Manufactured Products to fail to
meet any regulatory requirements. Except for such changes as may be contemplated by the Funded Projects set forth on Exhibit F, the terms of which are governed by Section 6.1, allocation of costs for such changes is further described in
Section 4.4(e). 
 (f) Work Order. In the event Cerus requires Fresenius Kabi to perform any work pursuant to this
Section 2.2, the Parties shall enter into a Work Order for the performance by Fresenius Kabi of such mutually-agreed services. Such services may include, but are not limited to, the conduct of annual stability studies and additional testing of
Manufactured Products beyond the scope currently set forth in this Agreement and the Quality Agreement. 
 Section 2.3 Supply and
Purchase Commitments. 
 (a) Subject to Cerus’ supply of (a) Platelet Wafers, Plasma Disks and S-59 for the Sets and
(b) S-303, GSH, RBC Filter Sets and RBC Processing Sets for the RBC Sets, during the Term of this Agreement, Fresenius Kabi shall supply Cerus with Manufactured Products within the delivery times required under Section 2.4. Cerus shall
purchase Manufactured Products from Fresenius Kabi as set forth in Section 2.5. 
 (b) Cerus shall purchase the following: 

(i) Except as set forth in this subsection “(i)”, Cerus shall purchase [ * ] of its requirements for Sets for the Territory
from Fresenius Kabi; provided, however, Cerus may purchase [ * ] of Sets from a third party [ * ]; provided further, Cerus shall be permitted to purchase Sets from a qualified third party supplier as cover for commercial purposes in the event of a
Supply Disruption. 
 (ii) Except as set forth in this subsection “(ii)” and subsection “(iii)” below, and subject to
successful completion of the activities required by Items “15 and 23” of the Funded Projects list in Exhibit F and as developed and defined by the Parties pursuant to Article 6 below, Cerus shall purchase [ * ] of its requirements
for RBC Sets for the Territory from Fresenius Kabi; provided, however, Cerus may purchase [ * ] of RBC Sets from a third party [ * ]; provided further, Cerus shall be permitted to purchase RBC Sets from a qualified third party supplier as cover for
commercial purposes in the event of a Supply Disruption. 
 (iii) Except as set forth in this subsection “(iii)”, and subject to
successful completion of the activities required by Items “15 and 23” of the Funded Projects as developed and defined by the Parties pursuant to Article 6 below, Cerus shall purchase [ * ] of its requirements for [ * ] for the Territory
from Fresenius Kabi, except to the prohibited by existing contractual obligations; provided, however, Cerus may purchase [ * ] of [ * ] from a third party [ * ]; provided further, Cerus shall be permitted to purchase [ * ] from a qualified third
party supplier 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 9 

 
as cover for commercial purposes in the event of a Supply Disruption. For clarity sake, it is understood by the Parties that Cerus currently has a contractual obligation to a third-party supplier
for the manufacture and supply of at [ * ] of Cerus’ annual total requirements for such [ * ] in the [ * ], provided such requirements do not exceed such third-party supplier’s production capacity, and in the case of the [ * ], that Cerus
has not implemented an [ * ]. It is further understood by the Parties that Cerus is party to a development agreement for such [ * ] and, upon validation and approval of such [ * ], the manufacture and supply of such [ * ] will be subject to certain
purchase requirements currently being negotiated by Cerus and such potential third-party supplier. Any rights by Fresenius Kabi to manufacture, and obligations by Cerus to purchase, such [ * ] shall be subject to the rights and obligations with
respect thereto to be set forth in the definitive manufacturing and supply agreement Cerus enters into with such third party supplier. It is further understood and agreed by the Parties that, in connection with any renewal rights Cerus may have with
respect to extending the initial term of the applicable definitive agreements for the manufacture and supply of the [ * ], Cerus shall [ * ]. Fresenius Kabi shall thereafter [ * ] and Cerus shall [ * ]; provided, however, that [ * ]. 

Section 2.4 Forecasts. 

In order to assist Fresenius Kabi in its production planning of Manufactured Products for Cerus, Cerus will provide to Fresenius Kabi during
the Term of this Agreement a [ * ] forecast by product code, of which the first [ * ] will constitute firm purchase orders for Platelet Sets, Plasma Sets and RBC Sets, and of which the first [ * ] will constitute firm purchase orders in the case of
Components ordered separately. With respect to the Sets, the [ * ] variation for the [ * ] constituting a firm purchase order shall not be greater than [ * ] of the average quantities ordered for the applicable Set in the preceding [ * ] period
unless otherwise agreed to by the Parties. Cerus agrees that these forecasts will include consideration of obligations for supply of products to meet the forecasts of any third party distributors or other third parties. Additionally, during the
third quarter of each calendar year, Cerus shall provide to Fresenius Kabi an “optimistic” volume forecast and a “base case” volume forecast, for the following [ * ]. “Optimistic” volume forecast shall be used for
manufacturing capacity assessment and discussion of manufacturing capacity planning between the Parties based on such assessment and shall be taken into account in the Business Continuity Plan. Monthly meetings with Fresenius Kabi and Cerus
representatives shall be held at a mutually agreeable time to discuss production planning and inventory management, including, but not limited to, volume forecasts provided pursuant to this Section 2.4, as well as Fresenius Kabi’ demand
forecasts for Cerus-Supplied Materials for the succeeding [ * ] period. 
 Section 2.5 Purchase Orders. 

The firm purchase orders in each rolling forecast described in Section 2.4 above will constitute a binding obligation on the part of
Cerus to purchase such Manufactured Products regardless of whether Cerus has a need for such Manufactured Products at the time of delivery and such purchase obligation will not be relieved for longer than a [ * ] period, except on account

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 10 

 
of any force majeure event or the unavailability of Cerus-supplied materials that may arise subsequent to the date the purchase order is placed. The terms and conditions of this Agreement will be
controlling over any terms and conditions included in any purchase order form used in ordering Manufactured Product. Any term or condition of any purchase order, invoice, packing slip, quotation or other document delivered by either Party incident
to the purchases hereunder that is in addition to, different from or contrary to the terms and conditions of this Agreement will be void, unless the Parties otherwise agree by a separate written agreement. 

Section 2.6 Delivery; Shipment; Invoices. 

(a) All Manufactured Products supplied under this Agreement will be delivered by Fresenius Kabi to Cerus’ designated carrier at the
Facility (FCA, La Châtre, France INCOTERMS 2010). Title and risk of loss passes to Cerus when the Manufactured Product has been received by Cerus’ designated carrier at such designated location. Fresenius Kabi shall issue invoices at
the time of release by Fresenius Kabi QA for delivery to Cerus, and Cerus shall pay said invoices within [ * ] days thereof. Disputed invoices are to be resolved expeditiously and in good faith by the Parties. Fresenius Kabi shall cause to be
delivered all Manufactured Products according to the [ * ] firm purchase orders ([ * ] firm purchase orders for Components, if ordered separately) made by Cerus pursuant to Section 2.4 of this Agreement. 

(b) Fresenius Kabi shall include a packing list in each shipment of the Manufactured Products providing the following information:
(1) Cerus purchase order number; (2) Fresenius Kabi Components Code; and (3) Quantity. Fresenius Kabi shall also mail a copy of each packing list to Cerus for each shipment at the time of shipment. Fresenius Kabi shall provide to
Cerus a certificate of compliance for each lot of Manufactured Products shipped. 
 (c) All Manufactured Product shall have a shelf life at
the time of release by Fresenius Kabi QA for receipt by Cerus’ designated carrier pursuant to Section 2.6(a) above of not less than the maximum shelf life (as set forth in the applicable Product Specification) less [ * ] or, with respect
to Manufactured Products reprocessed pursuant to Section 7.9 of the Quality Agreement, [ * ]. 
 (d) Within [ * ] of receipt of Product
Release Records (as defined in the Quality Agreement between the Parties) for Manufactured Products, Cerus will complete a review to identify any variations from the Product Specifications referenced on the relevant exhibit to this Agreement. If
Cerus delivers such notice of variation from Product Specifications within such [ * ] period, Cerus shall promptly make available to Fresenius Kabi for examination and testing, at the expense of Fresenius Kabi, the Manufactured Products in the
rejected shipment. Cerus will work with Fresenius Kabi to determine if the identified variations from Product Specifications can be clarified or resolved. If the parties are unable to agree on whether said Manufactured Products meet the
Specifications, samples of the same shall be provided to an independent qualified third party acceptable to both Cerus and Fresenius Kabi for such evaluation. The decision of said third party shall be binding on both parties. In the event the
Manufactured Product is found to not meet Specifications, Fresenius Kabi shall, at Fresenius Kabi’s expense, 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 11 

 
either (i) credit Cerus for the amount of such non-conforming Manufacturing Products for which Cerus has previously paid Fresenius Kabi, or (ii) promptly provide replacement
Manufactured Products that meet the Product Specifications. 
 Article 3 

Warranty 

Section 3.1 Warranty. 

(a) Each Party represents and warrants to the other as follows: 

(i) As of the Effective Date, all corporate action necessary for the authorization, execution and delivery of this Agreement by such Party and
the performance of its obligations hereunder has been taken; 
 (ii) As of the Effective Date, the execution, delivery and anticipated
performance of this Agreement do not violate or conflict with any law applicable to it, any provision of its charter or bylaws, any order or judgment of any court or other agency of government applicable to it or any of its assets or any contractual
restriction or provision or agreement or instruction binding on or affecting it or any of its assets; 
 (iii) As of the Effective Date, its
obligations hereunder constitute its legal, valid and binding obligations, enforceable in accordance with their respective terms (subject to applicable bankruptcy, reorganization, insolvency, moratorium or similar laws affecting creditors’
rights generally and subject, as to enforceability, to equitable principles of general application, regardless of whether enforcement is sought in a proceeding in equity or at law); and 

(iv) To the knowledge of the Parties as of the Effective Date, no consents, waivers, approval or authorizations of any third party, other than
the Regulatory Authorities in other countries in the Territory, are required for such Party to perform any of its obligations under this Agreement. 

(b) Fresenius Kabi represents and warrants that, upon shipment and for a [ * ] period from the date of production of each Manufactured Product
(or for the shelf-life of the Manufactured Product, if such period is longer) (the “Warranty Period”), Manufactured Products will meet the then-current Product Specifications, and be free from defects in material, workmanship and
title, provided Manufactured Products are stored according to label copy and are used according to label instructions; provided, however, for the avoidance of doubt, said warranty shall not apply to failures caused by the design of the Products
(except to the extent that such design was based on input from Fresenius Kabi) nor by Cerus-Supplied Materials. 
 (c) Subject to
Section 2.2(d), Fresenius Kabi represents and warrants that its manufacturing facilities used to provide Manufactured Products hereunder meet the QSRs, cGMP and standards applicable as required to meet the Product Specifications. 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 12 

 Section 3.2 Disclaimer of Warranties. With respect to the subject matter of
this Agreement, the warranties granted in Section 3.1 are exclusive and are offered in LIEU OF ALL IMPLIED OR STATUTORY WARRANTIES (INCLUDING WITHOUT LIMITATION, WARRANTIES AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ARISING
FROM COURSE OF DEALING OR USAGE OF TRADE) or any other express or implied warranties or representations. 
 Section 3.3
Remedies. If any item manufactured by Fresenius Kabi or its subcontractors shall prove defective in material and/or workmanship within the Warranty Period, Cerus shall notify Fresenius Kabi in writing of such defect or noncompliance as
soon as reasonably practicable, but in any event within [ * ] of Cerus’ discovery of such defect or noncompliance, and Fresenius Kabi shall replace said item. The Warranty Period for such replaced item shall be as set forth in
Section 3.1(b) of this Agreement. Fresenius Kabi shall have no responsibility if (a) such item has been improperly stored by Cerus or used outside of label instruction by Cerus, its agents or customers or (b) the defect or
noncompliance is due to an act or omission by Cerus or its third-party suppliers as relating to (i) with respect to the Sets, the Platelet Wafers, Plasma Disks, S-59 or INTERCEPT Illuminator devices, (ii) with respect to the RBC Sets, the
RBC Filtering Sets, RBC Processing Set [ * ], S-303 or GSH; or (iii) any other Cerus- Supplied Materials. The foregoing shall be Fresenius Kabi’s sole and exclusive liability and Cerus’ sole and exclusive remedy for any breach of
contract action arising out of any such defect, except with respect to each Party’s indemnification obligations as set forth in Article 11, provided that Fresenius Kabi shall remain responsible to carry out its obligations under the Quality
Agreement. 
 Article 4 

Payments; Audit; Steering Committee 

Section 4.1 Compensation for Manufacturing Services. 

(a) Transfer Pricing for Sets. The [ * ] transfer price at which the Sets will be invoiced to Cerus (the “Transfer
Price”) for the Current Pricing Term shall be determined based upon the [ * ]. The Transfer Price [ * ] is set forth on Exhibit D-1 and includes the “Cerus Transfer Price” for the Cerus-Supplied Materials as set
forth in Exhibit D-2. 
 (b) Transfer Pricing for Cerus-Supplied Materials. Cerus shall invoice Fresenius Kabi for the
Cerus-Supplied Materials at the “Cerus Discounted Transfer Price” for the applicable contract year, as set forth in Exhibit D-2, which amount includes a discount equal to a conversion loss allowance of [ * ]% for the Current
Pricing Term. For the Remainder Term, the conversion loss allowance will be reduced to reflect a reduced allowance mutually agreed upon by the Parties during the Negotiation Period based on the Conversion Loss Reduction Plan (as defined in
Section 4.2(b)). Cerus may, in its sole discretion, amend the Cerus Transfer Price as shown on Exhibit D-2 during the Term of this Agreement, which amendment shall result in an automatic corresponding adjustment to the Cerus Discounted
Transfer Price and the Transfer Price for Platelet Sets and/or Plasma Sets, as applicable, to reflect the impact of such amendment. 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 13 

 (c) Transfer Pricing for New Manufactured Products. The initial transfer price for
the RBC Sets, or any Components or New Product to be manufactured and supplied by Fresenius Kabi that is not manufactured and supplied by Fresenius Kabi to Cerus as of the Effective Date, shall be negotiated in good faith by the Parties and shall be
set at an amount equal to [ * ] percent ([ * ]%) of the Cost of Goods for the applicable product (the “New Product Transfer Price”); provided however, that the pricing for Intersol Solution shall be in accordance with
Section 18 of the Commercialization Agreement. Such New Product Transfer Price shall be fixed for a period of [ * ] years. Thereafter, adjustments to the New Product Transfer Price of such product shall be done in accordance with Sections
4.1(d) and (e) below. Further, the Parties shall negotiate in good faith discounted transfer pricing for such Components or New Products based on [ * ] consistent with the [ * ] set forth on Exhibit D-1. In order to verify the Cost of
Goods comprising the New Product Transfer Price pursuant to this Section 4.1(c), Fresenius Kabi shall provide to Cerus a written report of the calculation of the Cost of Goods for the applicable product at least [ * ] days prior to the
commencing manufacture of such Components or New Products, as applicable. Cerus shall have the right to cause an independent, certified public accounting firm selected from among the “Big 4” nationally recognized accounting firms, or such
other firm of national standing that is reasonably acceptable to Fresenius Kabi to audit Fresenius Kabi’ records relating to the Cost of Goods for such product to confirm the amount of the costs and expenses reflected in such report. The
accounting firm shall be obligated to keep in strict confidence his findings also vis-à-vis Cerus and will inform Cerus and Fresenius Kabi only about whether or not the calculation of the applicable New Product Transfer Price has been correct
and the amount, if any, of the deviation from the charged New Product Transfer Price. Cerus shall bear the full cost of such audit unless such audit discloses an over-charging by Fresenius Kabi of [ * ] percent ([ * ]%) or more, in which event
Fresenius Kabi shall bear the costs of such audit. 
 (d) Pricing Negotiation for New Pricing Terms. Pricing discussions with
respect to the Transfer Price to be in effect for each calendar year beginning with [ * ] through the remainder of the Initial Term (the “Remainder Term”) shall begin no later than [ * ], and the parties shall negotiate the new
Transfer Price for such Remainder Term in good faith, which new Transfer Price shall take effect beginning [ * ]. Pricing discussions with respect to the Transfer Price to be in effect for any Renewal Term shall be no later than September 1st of the calendar year preceding each such Renewal Term and shall be subject to the good faith negotiation of the Parties with respect thereto. 

(e) Transfer Pricing for New Pricing Term. New transfer pricing for any New Pricing Term shall take into account [ * ];
provided, however, any cost increase or decrease in raw materials or other components supplied by Fresenius Kabi, including, but not limited to, adjustments as a result of any change in the Product Specification or manufacturing lot size for a
Manufactured Product, shall result in [ * ] corresponding increase or decrease, as applicable, in the Transfer Price. In the event the Parties are not able to reach agreement on the new Transfer 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 14 

 
Price for a given New Pricing Term within the period from September 1st through December 31st of the calendar year preceding such New Pricing Term (the “Negotiation Period”), the new Transfer Price for the applicable New Pricing Term will be equal to [ * ]. In such event,
the Parties shall continue to attempt to reach agreement, and any such agreed Transfer Price shall be [ * ] made during the applicable New Pricing Term (and an invoice or credit issued as appropriate). 

Section 4.2 Cost Calculations 

(a) Raw Material Cost Changes. Cerus understands and acknowledges that Fresenius Kabi has supply agreements for key plastics
used in the Platelet and Plasma Sets, and that such agreements may result in raw materials cost changes, such cost changes to be passed through to Cerus as adjustments to the Fresenius Kabi Transfer Price to the extent provided in Section 4.1
of this Agreement. 
 (b) Conversion Loss. Fresenius Kabi shall use commercially reasonable efforts to continually reduce
conversion loss and rework for Manufactured Products and Cerus-Supplied Materials. For the purpose of this Agreement, “conversion loss” shall include losses due to quality control testing and scrap of excess or non-conforming Manufactured
Products. During the Current Pricing Term, the Parties will jointly prepare a development plan to reduce such conversion loss and rework for Manufactured Products and Cerus-Supplied Materials (the “Conversion Loss Reduction Plan”). 

(c) Scrap. Cerus agrees to pay [ * ] of scrap charges for excess materials, such as obsolete labels and instructions for use
(“IFUs”) arising from changes in Manufactured Products Specifications. Fresenius Kabi will promptly notify Cerus of the nature and amount of such scrap charges and invoice Cerus accordingly. 

Section 4.3 Steering Committee. 

(a) The Parties shall establish a Joint Steering Committee comprised of an equal number of representatives from Fresenius Kabi and Cerus (the
“Steering Committee”), which members shall initially be the individuals identified on Exhibit E. The Steering Committee shall meet at least twice per calendar year and shall have primary responsibility for providing oversight
with respect to: (i) execution of the Business Continuity Plan; (ii) the overall stability and long-term viability of the Facility for purposes of enabling Cerus to evaluate its rights and obligations under [ * ]; (iii) [ * ] upon
termination or expiration of Cerus’ contractual commitments as described in Section 2.3(b) and (iv) the preparation of detailed project plans, including scope, roles and responsibilities, prioritization and timelines with respect to
the Funded Projects. 
 (b) In addition to the responsibilities set forth in Section 4.3(a), the Steering Committee shall meet at least
twice per calendar year to perform the following tasks: 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 15 

 (i) Review and prioritize cost reduction initiatives, at which time, Cerus and Fresenius Kabi
shall identify projects for implementation (if any), and estimate and allocate related costs (including, but not limited to, engineering time, operating and capital expenses), and risks and benefits. 

(ii) Review and prioritize New Products and product improvements, and anticipated changes. 

(c) In the event that the Steering Committee is unable to reach a decision on any matter after [ * ] business days, the decision will be
escalated to the Chief Executive officer of Cerus and the designated member of the Management Board of Fresenius Kabi (together, the “Business Heads”), who will have an additional [ * ] business days to reach a mutually agreeable
decision. If the Business Heads are unable in good faith to reach resolution, the Parties shall submit the issue to an independent third party jointly selected by the parties for resolutions. The parties shall jointly bear the costs, if any, of such
third party. 
 (d) For the avoidance of doubt, and subject to Section 2.2, (i) Fresenius Kabi shall be able, without Cerus’
consent (or Steering Committee involvement), to implement any projects or other process improvements that do not affect product specifications or registrations, provided that such projects or process improvements do not result in an increase in
pricing, and (ii) Cerus shall not unreasonably withhold or delay its consent to initiate any projects or other process improvements that affect product registrations, provided that such projects or process improvements shall not be implemented
without Cerus’ consent and approval until any required Regulatory Approvals are obtained. 
 (e) For the avoidance of doubt, and
subject to Sections 2.2 and 6.2, (i) Cerus shall be able, without Fresenius Kabi consent (or Steering Committee involvement), to implement any projects or other process improvements, provided that the parties shall negotiate in good faith any
adjustment to pricing that may result from such projects or process improvements, and (ii) Fresenius Kabi shall not unreasonably withhold or delay its consent to any new products or product design changes. 

Section 4.4 Change Requests; Capital Expenditures. 

(a) Product Specifications. Except for such changes as may be contemplated by the Funded Projects set forth on Exhibit F, the
terms of which are governed by Section 6.1, in the event of any change in Product Specifications under Section 2.2, Fresenius Kabi will not be required to perform any work with respect to such change until the Parties reach written
agreement on the scope of the additional work, the roles and responsibilities of the Parties with respect to the execution of such change, the allocation of expenses and the change in Transfer Price. 

(b) Product Development; Product Improvements; Prototypes. Except as to the 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 16 

 
Funded Projects set forth on Exhibit F, the terms of which are governed by Section 6.1, at Cerus’ request, Fresenius Kabi will provide cost estimates for projected development work,
including any development work related to any Future Products (the “Unfunded Projects”). Cerus will reimburse Fresenius Kabi on a time and material basis for pre-approved out-of-pocket expenses, engineering trials, prototype
manufacturing for research and development (including costs of making changes or conducting activities described under Section 2.2(b)) and/or clinical trials, FTE support and materials) incurred in connection with such Unfunded Projects. 

(c) Manufacturing Location. Fresenius Kabi will bear any and all costs of relocating and revalidating manufacturing equipment
and facilities unless such relocation and validation is expressly requested by Cerus. Notwithstanding the foregoing, and subject to the limitations set forth in Section 2.2(c), Fresenius Kabi shall have the ability to amortize [ * ] of its
capital equipment costs incurred in connection with establishing the Second Facility for the manufacture of the Manufactured Products, up to a maximum of [ * ]. Except as otherwise provided herein, any costs involved with any change in manufacturing
relocation will not be included in the Transfer Price and will not increase the Transfer Price to Cerus over the Transfer Price that was then in effect as to any Manufactured Product that continues to be manufactured at the Facility. 

(d) Compliance with U.S. FDA QSRs and cGMP. The costs of maintaining (as to the Facility) and establishing (as to the Second
Facility) compliance with QSRs, cGMP and other regulatory standards for a Class III medical device pursuant to Section 2.2(d) will be borne by Fresenius Kabi. 

(e) Plastics. Cerus understands that significant testing costs may be required for the qualification and submission of potential
changes described in Section 2.2(e). Except as contemplated by the Funded Projects set forth on Exhibit F, Cerus agrees to fully fund any qualification and validation work required specifically for use of plastics in the Manufactured Products.
Fresenius Kabi will fund the generic qualification and validation work that would be required for material changes required for use of such plastics in Fresenius Kabi products. 

(f) Capital Expenditures. Except as provided in Sections 4.4(c) or (d), and except for (i) any cost of relocating
manufacturing facilities, (ii) identifying and qualifying the Second Facility as contemplated by Section 2.3(c), (iii) providing sufficient capacity for Manufactured Products to Cerus and/or (iv) any costs contemplated by the
Funded Projects, each of which will be Fresenius Kabi’s financial responsibility, any capital expenditure required exclusively to meet the changes requested by Regulatory Authorities will be paid for directly by Cerus. Any such capital assets
paid for by Cerus (“Cerus Assets”) shall be purchased in Cerus’ name and be owned by Cerus. Fresenius Kabi shall be liable for all risk of damage to or loss of such Cerus Assets while in the possession or control of Fresenius
Kabi, ordinary wear and tear excepted. Fresenius Kabi shall tag all such Cerus Assets in its possession or control with appropriate indicators that they are owned by Cerus, and shall ensure that no third party acquires any security interest in the
Cerus Assets while they are in the possession or control of Fresenius Kabi. All Cerus Assets in the possession or control of Fresenius Kabi shall be returned to Cerus upon the termination of this Agreement. 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 17 

 Section 4.5 Payment; Late Payment Charges. Cerus will pay any purchase price
or payment for services due hereunder in Euros in the event Euros are the local currency of the manufacturing site or site of performance of services, and in U.S. Dollars in all other cases, unless the Parties otherwise agree in writing. Such
payments shall be made within [ * ] days after the date of Fresenius Kabi’s invoice by check or wire transfer to a bank account designated in writing by Fresenius Kabi. Undisputed invoices not timely paid will be subject to a late payment
charge of [ * ] percent ([ * ]%) per month, or the highest amount permitted by law, if lower. 
 Article 5 

Cerus-Supplied Materials; PL-2410; Illuminators 

Section 5.1 Cerus-Supplied Materials. 

(a) Cerus shall have full management and control of the supply chain for certain Components (“Cerus-Supplied Materials”),
including, but not limited to, specifications, qualification, change control, purchasing of certain raw materials, production planning and facility expansion, and OEM relationships with third party suppliers. Cerus shall have the right to enter
directly into contractual arrangements with such third party suppliers for said purposes. Any agreement with third party suppliers designated as such by Cerus (as of the Effective Date, [Grifols S.A., Biomedica Foscama Group S.p.A., Albany Molecular
Research, Inc., Baxter Oncology GmbH,] The Purolite Company, Powdersize, Inc., and Porex Corporation) shall provide for the release of Cerus-Supplied Materials according to Cerus specifications. Cerus shall have the responsibility to resolve
technical issues with third party suppliers related to the supply of Cerus-Supplied Materials. The Parties acknowledge that Cerus has had, and agree that Cerus shall continue to have, full management and control of the supply chain for S-59,
including, but not limited to, specifications, qualification, change control, forecasting, purchasing and development studies. For all Components manufactured by Fresenius Kabi, the responsibilities set forth in in this Section 5.1(a) with
respect to the management and control of the supply chain for such Components shall be borne by Fresenius Kabi. This Section supersedes Section 15(d) of the Commercialization Agreement. 

(b) During the Current Pricing Term, Fresenius Kabi agrees to purchase from Cerus and store Cerus-Supplied Materials at a level of inventory
of [ * ], based on third party supplier lead times and [ * ] forecasts provided by Cerus. During the Negotiation Period, the Parties will mutually agree upon an appropriate inventory level for the applicable New Pricing Term. 

(c) Once released, Fresenius Kabi shall arrange for shipment of any Cerus-Supplied Materials from the applicable third party
manufacturer’s facilities to Fresenius Kabi’s receiving facility. Fresenius Kabi shall be the importer of records for import of any Cerus-Supplied Materials into the European Union and for VAT purposes. As such, Fresenius Kabi shall be
responsible for preparing and filing documentation, and paying related fees, as required by 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 18 

 
applicable laws, rules and regulations, to import such goods in the European Union. Fresenius Kabi will notify Cerus upon (i) receipt of each shipment of Cerus-Supplied Materials; and,
(ii) upon completion of acceptance testing for such Cerus-Supplied Materials, as applicable. Title to Cerus-Supplied Materials shall transfer to Fresenius Kabi upon receipt of such Cerus-Supplied Materials from the applicable third party
manufacturer’s facilities. 
 Section 5.2 PL-2410. Fresenius Kabi agrees to continue to supply Cerus PL-2410 resin
(or alternate resin once qualified) for use in the production of Platelet Wafers. 
 Section 5.3 Illuminators. Cerus
shall take full management and control of the supply chain for INTERCEPT Illuminator devices, including, but not limited to, OEM relationships, inventory, obsolescence planning and change control, and Cerus shall have the right to enter directly
into contractual arrangements with third party suppliers (such as Nova Biomedical Corporation) for the supply and manufacturing of such devices. Cerus shall continue to have the responsibility for field service, resolving technical issues with third
party suppliers related to the supply and manufacturing of INTERCEPT Illuminator devices. This Section supersedes Section 15(e) of the Commercialization Agreement. 

Section 5.4 Inspection of physical inventory. During the Term, and no more than twice a year or for cause, Cerus shall have
the right to conduct a physical inspection and reconciliation of Cerus owned Manufactured Products and inventory, at the Facility and during normal business hours, in order to ascertain or verify the number and description of Manufactured Products
held by Fresenius or in the process of being manufactured. Cerus shall endeavor to give Fresenius at least [ * ] days’ notice prior to arrival for such physical inspection. Fresenius shall use commercially reasonable efforts to cooperate with
Cerus in the inventory inspection. 
 Article 6 

Funded Projects; Future Products 

Section 6.1 Funded Projects.  

(a) To further the collaboration between the Parties, the Parties agree to undertake the development of the Funded Projects according to
the phasing and as otherwise set forth in Exhibit F and Section 6.1(d) below. Each Party shall use its commercially reasonable efforts to successfully complete the Funded Projects, including obtaining the necessary product registrations and
Regulatory Approvals. The Parties may subsequently identify additional Funded Projects, which Additional Funded Projects must be mutually agreed upon and set forth in an amendment to this Agreement. 

(b) Each Party shall appoint one or more contact persons to serve as project manager for the Funded Projects, which persons shall manage all
aspects of the collaboration, including 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 19 

 
development, validation and regulatory status and timelines, and means to reduce costs and increase efficiencies of both Parties. Cerus shall be responsible for developing the specifications and
project codes for any New Products resulting from the Funded Projects, subject to Fresenius Kabi’ review and approval, which shall not be unreasonably withheld or delayed. Fresenius Kabi shall be responsible for managing meetings and taking
meeting minutes to document the progress of the Funded Projects, which minutes shall be jointly reviewed and approved. 
 (c) Fresenius Kabi
agrees to fully fund the Funded Projects, including, but not limited to, any facility costs, capital expenditures, labor and equipment costs, material costs, costs associated with producing prototype, clinical and registration lots, costs associated
with any required manufacturing validation studies, and costs associated with design verification studies related to the physical products, such as biocompatibility, stability, aging, packaging, distribution, functionality, and integrity studies, in
each case to the extent reasonably attributable to such Funded Projects (the “Funded Development Costs”). Notwithstanding the foregoing, Cerus agrees to contribute [ * ] towards the Funded Development Costs, payable as follows:
(i) [ * ] shall be payable on [ * ], and (ii) [ * ] shall be payable on [ * ]. For the avoidance of doubt, nothing in this Agreement including this Section 6.1 shall require Fresenius Kabi to pay or reimburse any costs of or expenses
incurred by Cerus in relation to Funded Projects for in vitro or clinical verification and validation studies of the products for their intended use of ex vivo treatment of blood components intended for transfusion or for any samples of Manufactured
Products provided to Cerus’ customers. 
 (d) It is understood and agreed by the Parties that the Phase 4 Projects will be initiated
upon achievement of the Phase 4 Project Milestone. Notwithstanding the foregoing, Fresenius Kabi agrees to complete and provide to Cerus a feasibility assessment and project plan with respect to each of the Phase 4 Projects by the date indicated for
such Phase 4 Project in Exhibit F. 
 Section 6.2 Future Products.  

(a) From time to time the Parties may collaborate on the development of new products not contemplated by the Funded Projects set forth on
Exhibit F (“Future Products”). Each Party agrees to use its commercially reasonable efforts to successfully complete any development and validation work required to obtain the necessary product registrations and Regulatory Approvals
with respect to such Future Products. 
 (b) Each Party shall appoint one or more contact persons to serve as project manager for any Future
Product under development, which persons shall manage all aspects of the collaboration, including development, validation and regulatory status and timelines, and means to reduce costs and increase efficiencies of both Parties. Cerus shall be
responsible for developing the specifications and project codes for such Future Products, subject to Fresenius Kabi’ review and approval, which shall not be unreasonably withheld or delayed. Fresenius Kabi shall be responsible for managing
meetings and taking meeting minutes to document the progress of such Future Products, which minutes shall be jointly reviewed and approved. 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 20 

 Article 7 

Term; Termination 

Section 7.1 Term.  

(a) The term of this Agreement shall be from the Effective Date of execution through July 1, 2025, unless earlier terminated
pursuant to Section 7.2 (the “Initial Term”). Upon expiration of the Initial Term, the term of this Agreement will automatically renew for additional successive two (2) year periods (each, a “Renewal Term”
and together with the Initial Term, the “Term”) unless (i) either Party provides written notice of non-renewal (A) with respect to the Initial Term, at least two (2) years prior to the expiration of the Initial Term,
and (B) with respect to any Renewal Term, at least one (1) year prior to the expiration of such Renewal Term, or (ii) such Renewal Term is earlier terminated pursuant to the terms of this Agreement or applicable law or regulation. If
the Initial Term or any Renewal Term is renewed for any Renewal Term(s) pursuant to this Section 7.1, the terms and conditions of this Agreement during each such Renewal Term will be the same as the terms in effect immediately prior to such
renewal. In the event that either Party provides timely notice of its intent not to renew this Agreement, then, unless earlier terminated in accordance with its terms, this Agreement terminates upon the expiration of the Initial Term or the
then-current Renewal Term, as applicable. 
 (b) Notwithstanding the termination provisions set forth in Section 7.1(a) or termination
pursuant to Section 7.2, in the event that Cerus is materially impeded from manufacturing, or having third parties manufacture Manufactured Products due to Fresenius Kabi’s patents, know-how or materials, such as plastics, seals,
connectors and sterilization, that have been excluded from the licenses to Cerus under the License Agreement, Fresenius Kabi will either (a) continue to supply to Cerus the specific items whose manufacture is impeded by such excluded rights for
so long as Cerus requires such items, or (b) expand the license under the License Agreement so as to eliminate such impediment. 
 (c)
Notwithstanding any other provision hereof, it shall be a precondition to termination of Fresenius Kabi’s obligations under this Agreement that Fresenius Kabi shall have furnished to Cerus all information to be provided under this Agreement and
the Licensed Materials to be provided under the License Agreement (as such term is defined in the License Agreement) at least thirty (30) months prior to such termination. This provision is not intended to relieve Fresenius Kabi from any
obligation stated herein or in the License Agreement to furnish to Cerus information and Licensed Materials sooner than such time. 

Section 7.2 Termination. This Agreement may be terminated as follows: 

(a) by Fresenius Kabi and Cerus upon their mutual agreement; 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 21 

 (b) by Fresenius Kabi or Cerus upon a material breach of this Agreement by the other Party,
provided, however, that the Party allegedly in breach shall be entitled to written notice of such breach and thirty (30) days to cure such breach (or such longer period as may be necessary if such Party has commenced curing such breach and is
diligently proceeding to cure such breach) before the Agreement may be terminated; and 
 (e) by Fresenius Kabi or Cerus with written notice
to take effect immediately upon receipt thereof by the other Party in the event that the Party receiving notice has filed for bankruptcy or is adjudged insolvent or has made an assignment for the benefit of creditors, or a receiver is appointed for
its business or a voluntary or involuntary petition of bankruptcy is filed, or proceedings for the reorganization of the Party are instituted. 

Section 7.3 Survival. The following provisions of this Agreement will survive any expiration or earlier termination of this
Agreement: Sections 2.6, 3.1, 3.2, 3.3, 4.4, 4.5, 5.2, 7.1, 7.3, 8.1, 8.2, and Articles 9, 10, 11 and 12. 
 Article 8 

Quality 

Section 8.1 Manufacturing Quality. Fresenius Kabi shall perform the obligations in accordance with the Quality Agreement.
All Manufactured Products shall be subjected to quality control inspections by Fresenius Kabi in accordance with Fresenius Kabi’s quality control standards and system and by Cerus to ensure adherence to the obligations set forth in the Quality
Agreement. 
 Section 8.2 Adverse Information. Each Party will promptly notify the other Party following receipt of any
information, including but not limited to any problems regarding the Manufactured Products or any information regarding any threatened or pending action that might affect the production or marketing of the Manufactured Products. Cerus, as holder of
the regulatory approvals and marketing authorization for the Manufactured Products, shall be solely responsible to make a timely report of such matter as necessary to any Regulatory Authority or take other action that it deems to be appropriate or
required under applicable law or regulation. Cerus shall determine the plan setting forth the appropriate actions for addressing any problems report with respect to any Manufactured Products and Fresenius Kabi will provide its full cooperation and
attention with respect to carrying out such plan. 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 22 

 Article 9 

Additional Covenants 

Section 9.1. Acquisition of Residual Inventory. Upon the expiration or termination of this Agreement, Cerus shall purchase
all existing inventory of Manufactured Products and Components, which shall include any or all work-in-process or raw materials to the extent specifically identified for Cerus. Notwithstanding the foregoing, Cerus shall have no obligation to
purchase any such inventory to the extent that it exceeds Cerus’ forecasted requirements for the [ * ] period after such expiration or termination or fails to meet the applicable Product Specifications or the shelf-life requirement set forth in
Section 2.6(c), with the exception of any inventory specifically requested by Cerus to be held, unless otherwise agreed in writing by the Parties. 

Section 9.2 Technology Transfer and Technical Assistance. Subject to the terms and conditions of the License Agreement, in
the event of (a) [ * ]; (b) Fresenius Kabi’s election to terminate this Agreement or (c) a Supply Disruption, Fresenius Kabi shall promptly transfer to Cerus all technical information pertaining to the manufacturing and
quality testing of the Manufactured Products (including without limitation, Bills of Materials, SOPs for manufacturing quality assurance and quality control, design history files and batch records, and including HUD, CER, etc. documents, technical
reports and regulatory submissions) and provide to Cerus technical experts to assist, consult and cooperate with technical personnel of Cerus or its manufacturing sublicensee in the design, production, inspection and maintenance of the Manufactured
Products; provided, however, that any technical information transferred in connection with a Supply Disruption shall only be used for the limited purpose of meeting Cerus’ supply requirements for the duration of such Supply Disruption and any
agreement with a qualified third party supplier having access to such technical information shall have a limitation on the use of such technical information consistent herewith. Cerus may make requests for technical assistance during the Term of
this Agreement, however, not to exceed two such requests a calendar year and one such request for each manufacturing change Fresenius Kabi may introduce. Cerus has the rights to use such information provided by Fresenius Kabi in accordance with the
terms of the License Agreement. Cerus shall pay the reasonable traveling, living and other related expenses of such technicians of Fresenius Kabi as agreed between the Parties, and Cerus shall pay for such services on an hourly rate (excluding
travel time) equal to $[ * ] (US) per day per person. Fresenius Kabi shall arrange at the request of Cerus for the visit of Cerus’ technical personnel to the offices or plants or any other facilities of Fresenius Kabi for the study of
manufacturing processes, practices, testing shipment and know-how used by Fresenius Kabi in the manufacture of the Manufactured Products as provided for under the License Agreement. In no event will Fresenius Kabi technicians be expected to meet or
travel for Cerus to a country for which the U.S. Department of State has issued a travel advisory recommending U.S. citizens leave or avoid traveling to such country at that time. 

Section 9.3 Compliance with Laws. Each Party will comply with all applicable laws, rules, ordinances and regulations of any
governmental entity or Regulatory Authority governing the Manufacturing Services to be provided hereunder. No Party will take any action in violation 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 23 

 
of any applicable law, rule, ordinance or regulation that could result in liability being imposed on the other Party. Fresenius Kabi will comply at all times with then current ISO standards and
then current Good Manufacturing Practices (cGMP) and maintain related certification, subject to Section 2.2(d). 
 Section 9.4
Relationship of the Parties. Fresenius Kabi shall and will remain at all times an independent contractor of Cerus in the performance of all Manufacturing Services hereunder. In all matters relating to this Agreement, each Party hereto
will be solely responsible for the acts of its employees and agents, and employees or agents of one Party shall not be considered employees or agents of the other Party. No Party will have any right, power or authority to create any obligation,
express or implied, on behalf of any other Party nor shall either Party act or represent or hold itself out as having authority to act as an agent or partner of the other Party, or in any way bind or commit the other Party to any obligations.
Nothing in this Agreement is intended to create or constitute a joint venture, partnership, agency, trust or other association of any kind between the parties or persons referred to herein. 

Section 9.5 Purchase of Equipment; Leasing of Facilities. In the event that [ * ], upon termination of Fresenius
Kabi’s obligations under this Agreement and as long as Fresenius Kabi has no obligations for Manufactured Products to either Cerus or its successors or assigns, Cerus may elect to purchase any equipment, instruments, tools, ties and molds
dedicated to the manufacturing of the Manufactured Products at a price to be negotiated by the Parties in good faith. Cerus may also elect to lease from Fresenius Kabi at a reasonable rental those portions of facilities dedicated to the
manufacturing of the Manufactured Products. 
 Section 9.6 Milestone Payment. Cerus shall make a one-time, lump sum
payment of [ * ] to Fresenius Kabi on December 31st of the earlier to occur of (a) the year in which [ * ] production volume [ * ] and (b) 2022. 

Section 9.7 [ * ] 

Section 9.8 Amendment to License Agreement. Effective as of the Effective Date, the license granted by the License
Agreement shall be converted to a royalty-free license. For purposes of clarity, no royalties will be assessed with respect to Net Sales of Products (in each case, as defined in the License Agreement) occurring on or after the Effective Date. 

Article 10 

Confidentiality 

Section 10.1 Confidential Information. All information and materials containing information provided by any Party to
another relating to this Agreement, including but not limited to customer requirements, lists, preferences and methods of operation, the technology, any know-how, data, process, or technique of any Party relating to such Party’s products, and
any research project, work-in-process, future development, scientific, engineering, or manufacturing information, know-how, designs, drawings, management information reports and 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 24 

 
other computer-generated reports, financial information, pricing policies and details, details of contracts, operational methods, plans or strategies, business acquisition plans, and the business
affairs of such Party, whether in oral, graphic or written form, as the case may be, are and shall be treated as confidential (“Confidential Information”). Among other things, Confidential Information shall include confidential or
proprietary information or materials of third parties and the Parties’ respective Affiliates, that are in the possession of one of the Parties and provided pursuant to this Agreement. 

Section 10.2 Obligations. Except as expressly authorized by prior written consent of the disclosing Party, the receiving
Party shall: 
  

	 	(a)	limit access to any Confidential Information of the disclosing Party received by it to its, its Affiliates’, sublicensees’ and distributors’ employees, agents, representatives, and consultants who have a
need-to-know in connection with this Agreement and the rights and obligations of the Parties hereunder, and who are under appropriate non-use and non-disclosure restrictions which are at least as restrictive as those set forth herein;

  

	 	(b)	safeguard all Confidential Information of the disclosing Party received using a reasonable degree of care, but not less than that degree of care used by the receiving Party in safeguarding its own confidential
information or material; and 

  

	 	(c)	use the Confidential Information of the disclosing Party only for the purposes and in connection with the performance of such Party’s obligations set forth in this Agreement. 

Section 10.3 Exceptions to Confidentiality. Notwithstanding Section 10.2, the Parties’ obligations of
confidentiality and non-use shall not apply to any particular information or materials that the receiving Party can demonstrate: 
  

	 	(a)	was, at the time of disclosure to it, in the public domain; 

  

	 	(b)	after disclosure to it, is published or otherwise becomes part of the public domain through no fault of the receiving Party; 

  

	 	(c)	was received after disclosure to it from a third party who had a lawful right to disclose such information or materials to it; 

  

	 	(d)	was required to be disclosed to any regulatory body having jurisdiction over the receiving Party or any of its respective Affiliates, sublicensees or customers; 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 25 

	 	(e)	that disclosure is necessary by reason of applicable legal, accounting or regulatory requirements beyond the reasonable control of the receiving Party; or 

 

	 	(f)	is subsequently developed by the receiving Party independently of the information received from the disclosing Party. 

In the case of any disclosure pursuant to Sections 10.3(d) or 10.3(e), to the extent practical, the receiving Party shall notify the disclosing Party in
advance of the required disclosure and shall use commercially reasonable efforts to assist the disclosing Party in obtaining a protective order, if available, covering such disclosure. If such a protective order is obtained, such information and
materials shall continue to be deemed to be Confidential Information. 
 Notwithstanding Section 10.2, Cerus shall have the right to disclose
Confidential Information of Fresenius Kabi to its attorneys, accountants, actual or potential sources of financing, and actual or potential investors or acquirers under appropriate non-use and non-disclosure restrictions which are at least as
restrictive as those set forth herein. 
 Section 10.4 Use of Certain Information. No Party shall, without the
appropriate Party’s prior written consent, use the names, service marks or trademarks of another Party as trademarks or use such names, service marks or trademarks to suggest any affiliation, sponsorship, endorsement or recommendation. All
employees, agents, representatives and consultants of each Party and its Affiliates and sublicensees shall be required to comply with the terms of this Section 10, and each Party, as applicable, shall be responsible for any breach thereof and
the performance or non-performance of each such party.  
 Section 10.5 No Publicity. Except as required by law,
no Party shall originate any news release or other public announcement relating to this Agreement or the terms hereof without the prior written approval of the other Party; provided, however that any Party to this Agreement may provide public
information concerning this transaction to the extent necessary or appropriate to comply with applicable securities laws and/or customary corporate communications processes. Notwithstanding the foregoing, Fresenius Kabi and Cerus shall make a joint
public announcement of the execution of this Agreement, in the form mutually agreed upon by the Parties, no later than five (5) business days following the Effective Date. 

Section 10.6 Equitable Remedies. Each Party acknowledges that if it, its Affiliates or their respective employees, agents,
representatives, or consultants breach (or attempt to breach) the obligations set forth in this Article 10, the other Party will suffer immediate and irreparable harm, it being acknowledged that legal remedies are inadequate. Accordingly, if a court
of competent jurisdiction should find that any such Party has breached (or attempted to breach) any such obligations, such Party shall not oppose the entry of an appropriate order compelling performance by such Party and restraining it from any
further breaches (or attempted breaches). 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 26 

 Article 11 

Indemnification; Insurance; Liability Limitation 

Section 11.1 Indemnification. 

(a) Intellectual Property Indemnification by Fresenius Kabi. Fresenius Kabi will, indemnify, defend and hold harmless Cerus and
its Affiliates, and their respective officers, directors, agents, and employees (collectively, with respect to Cerus, the “Cerus Indemnified Parties”) from and against any Damages arising out of or relating to any claim from any
third party that Fresenius Kabi’s plastics, subassemblies, such as bags, tubing and connectors, or manufacturing or packaging processes for the Manufactured Products (the “Fresenius Kabi Elements”), infringe, misappropriate or
violate any patent, copyright, trade secret, confidential information or other intellectual property of any third party. 
 (b)
Exceptions to Fresenius Kabi Intellectual Property Indemnification. Fresenius Kabi shall have no indemnification obligations under Section 11.1(a) with respect to any infringement relating to: 

(i) Cerus’ direction, without Fresenius Kabi’s approval, to any Person to use the Manufactured Products in a manner contrary to the
instructions for use of such Manufactured Product and the infringement is caused by such contrary use; or 
 (ii) the combination,
incorporation or use of any Manufactured Products by Cerus with Cerus’ or any third party’s product(s), or the use of such combined or incorporated Manufactured Products by Cerus’ customers, if such infringement would not have existed
but for such combination or incorporation of the Manufactured Products by Cerus with or into any such Cerus product or any other third party product, or the use of such combined or incorporated product by Cerus’ customers, except for
combinations, incorporations or use specified in the instructions for use of such Manufactured Products. 
 (c) Intellectual Property
Indemnification by Cerus. Cerus will indemnify, defend and hold harmless Fresenius Kabi and its Affiliates, and their respective officers, directors, agents, and employees (collectively, with respect to Fresenius Kabi, the “Fresenius
Kabi Indemnified Parties”) from and against any Damages arising out of or relating to any claim from any third party that any Cerus-Supplied Materials or Manufactured Product infringes, misappropriates or violates any patent, copyright,
trademark, trade secret, confidential information or other intellectual property right of any third party; provided that the indemnification obligation set forth in this Section 11.1(c) shall not apply to the extent that such Damages arise out
of or relate to (i) a Fresenius Kabi Element or (ii) the Licensed Assets, or (iii) a Manufactured Product that is not in conformity with the Product Specifications and such infringement, misappropriation or violation would not have
existed but for the difference between the specifications and the Product Specifications. 
 (d) Other Indemnification by Fresenius
Kabi. Fresenius Kabi will indemnify, 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 27 

 
defend and hold harmless the Cerus Indemnified Parties from and against any Damages arising out of or relating to any claim from any third party that defective Manufactured Product, negligence or
willful misconduct of Fresenius Kabi, or acts or omissions of Fresenius Kabi that would constitute a Breach, have created Liabilities to the third party; provided, however, for the avoidance of doubt, Fresenius Kabi shall have no obligation to
indemnify Cerus for any Liabilities caused by (i) the design of the Products (except to the extent that such design was based on input from Fresenius Kabi), (ii) Cerus-Supplied Materials, or (iii) any claim encompassed within
Cerus’ obligation to indemnify pursuant to Section 11(e) below. 
 (e) Other Indemnification by Cerus. Cerus will
indemnify, defend and hold harmless the Fresenius Kabi Indemnified Parties from and against any Damages arising out of or relating to any claim from any third party (other than claims of infringement of patent, copyright, trademark, trade secret,
confidential information or other intellectual property right) that Cerus’ or its distributors’, resellers’ or Affiliates’ sale, offer for sale, import, manufacture, use or distribution of Manufactured Products, or use of such
Manufactured Products by customers of Cerus, has created Liabilities to the third party; except to the extent the claim is encompassed within Fresenius Kabi’s obligation to indemnify pursuant to Section 11.1(d), above. 

Section 11.2 Procedure for Indemnification - Third Party Claims. 

(a) Promptly after receipt by an Indemnified Party of notice of the commencement of any Proceeding against it, the Indemnified Party shall
notify the other Parties obligated to indemnify such Indemnified Party (the “Indemnifying Party”) of the commencement of the claim. 

(b) If any Proceeding referred to in Section 11.2(a) is brought against an Indemnified Party and it gives notice to the Indemnifying
Party of the commencement of the Proceeding, the Indemnifying Party shall, upon written notice given within thirty (30) days after the Indemnified Party’s notice is given, be entitled to assume the defense of the Proceeding. If the
Indemnifying Party elects to assume the defense of a Proceeding, the Indemnified Party shall turn the Proceeding over to the Indemnifying Party, who shall, at its own expense, assume the defense of the Proceeding and the Indemnified Party shall have
the right (but not the obligation) to participate, at its own expense, in the defense thereof by counsel of its own choice, and shall cooperate with and assist the Indemnifying Party in connection with the defense or contest, but the Indemnifying
Party shall retain control thereof and have final authority to determine all matters in connection therewith. Notwithstanding the foregoing, (i) the Indemnifying Party shall have the right to control the defense, litigation and settlement of
the action only if the Indemnifying Party has agreed in writing to be responsible for all costs, expenses, judgments and liabilities connected with the claim, (ii) the Indemnifying Party shall not enter into any settlement of any Proceeding
unless such settlement is contingent upon obtaining a general release in form and substance acceptable to the Indemnified Party releasing the Indemnified Party from all Liabilities in such Proceeding, and (iii) the Indemnifying Party shall not
enter into any settlement of any Proceeding if such settlement grants any injunctive or equitable relief unless the Indemnified Party has consented in writing to such settlement. 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 28 

 Section 11.3 Definitions. 

(a) As used herein, a “Breach” shall mean a breach of a covenant, obligation or other provision of this Agreement, and such
breach will be deemed to have occurred if there is or has been one or more misstatements or inaccuracies in, or one or more failures to perform or comply with, any representation, warranty, covenant, obligation or other provision of this Agreement.

 (b) As used herein, “Damages” shall mean all Liabilities, obligations, losses, damages, deficiencies, assessments,
judgments, costs, expenses (including, without limitation, reasonable attorneys’ fees and costs and expenses incurred in investigating, preparing, defending against or prosecuting any Proceeding). 

(c) As used herein, “Liabilities” means any debts, obligations, duties or liabilities of any nature, whether known or
unknown, and whether accrued, contingent or otherwise. 
 (d) As used herein, “Proceeding” means any third-party action,
arbitration, audit, hearing, investigation, litigation or suit (whether civil, criminal, administrative, investigative or informal) commenced, brought, conducted or heard by or before, or otherwise involving, any governmental body or arbitrator.

 Section 11.4 Fresenius Kabi Insurance. Fresenius Kabi shall carry appropriate levels of insurance coverage consistent
with its commercially reasonable business practices. 
 Section 11.5 Cerus Insurance. Cerus shall carry appropriate
levels of insurance coverage consistent with its commercially reasonable business practices. 
 Section 11.6 Limitation on
Liability. In no event shall any Party be liable for incidental or consequential damages regardless of whether such Party shall be advised, shall have other reason to know, or in fact shall know of the foregoing, in excess of [ * ] U.S.
dollars (U.S. $[ * ]) in the aggregate under this Agreement. 
 Article 12 

Miscellaneous 

Section 12.1 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of
Delaware. 
 Section 12.2 Assignment and Delegation. 

(a) No Assignments Except as Permitted. No Party may assign any of its rights under this Agreement other than assignments
to a Permitted Assignee, except with the prior written consent of the other Party. That Party shall not unreasonably withhold its consent. 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 29 

 
“Permitted Assignees” include an Affiliate of the assigning Party and a third party to whom the assigning Party transfers substantially all of the products, business and services
to which this Agreement relates and who assumes all obligations of the assigning party under this Agreement and has the capability to perform such obligations. All other assignments of rights are prohibited under this subsection, whether they are
voluntary or involuntary, by merger, consolidation, dissolution, operation of law, or any other manner. For purposes of this Section, (i) a “change of control” is deemed an assignment of rights; and (ii) “merger” refers
to any merger in which a Party participates, regardless of whether it is the surviving or disappearing corporation. 
 (b) No
Delegations. No Party may delegate any performance under this Agreement. 
 (c) Ramifications of Purported Assignment
or Delegation. Any purported assignment of rights or delegation of performance in violation of this Section is void. 

Section 12.3 Successors and Assigns. This Agreement inures to the benefit of, and is binding upon, the successors and
assigns of the Parties hereto. 
 Section 12.4 Entire Agreement; Amendments. This Agreement contain the entire
understanding of the Parties with regard to the subject matter contained herein and thereon, and supersede all prior agreements or understandings between Cerus and Fresenius Kabi with respect to the subject matter of the Original Supply Agreement.
For purposes of clarity, except as stated in Sections 5.1 and 5.3(a) of this Agreement, this Agreement does not supersede the Commercialization Agreement, the Restructuring Agreement entered between the Parties as of February 2, 2005, or the
Concurrent Agreement (as defined in the Restructuring Agreement). For further clarity, except as stated in Section 9.8 of this Agreement, this Agreement does not supersede or amend the terms of the License Agreement, which governs the terms of
any intellectual property applicable to the rights and obligations of the Parties hereunder. This Agreement will not be amended, modified or supplemented except by a written instrument signed by an authorized representative of each of the Parties.

 Section 12.5 Force Majeure. Neither Party will be deemed in default if delayed or prevented from performing its
obligations under this Agreement, in whole or in part, due to an act of God, fire, flood, explosion, civil disorder, strike, lockout or other labor trouble, material shortages of utilities, equipment, materials or facilities, delay in
transportation, breakdown or accident, riot, war, terrorist attack or other cause beyond its control (a “Force Majeure Event”); provided that it shall resume full performance of this Agreement as soon as practicable following the
conclusion of the Force Majeure Event. 
 Section 12.6 Interpretation; No Strict Construction. Article titles and
headings to Sections herein are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. The language used in this Agreement shall be deemed to be the language
chosen by the Parties hereto to express their mutual intent, and no rule of strict construction shall be applied against any Party hereto. 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 30 

 Section 12.7 Partial Invalidity. If any provision of this Agreement, or the
application thereof, is held by a court of competent jurisdiction to be invalid, void or unenforceable, the remainder of the provisions of this Agreement will in no way be effected, impaired or invalidated, and to the extent permitted by applicable
law, any such provision will be restricted in applicability or reformed to the minimum extent required for such provision to be enforceable. 

Section 12.8 No Third Party Beneficiary. This Agreement will not confer any rights or remedies on any person other than the
Parties hereto and their respective successors and permitted assigns. 
 Section 12.9 Counterparts. This Agreement may be
executed in one or more counterparts (and by facsimile), all of which shall be considered one and the same agreement, and shall become effective when one or more counterparts have been signed by each of the Parties and delivered to the other
parties. 
 Section 12.10 Notices. Wherever under this Agreement one Party is required or permitted to give written
notice to the other, such notice will be deemed given if made in accordance with the terms of the License Agreement. 

Section 12.11 Nonwaiver. No alleged waiver, modification or amendment to this Agreement shall be effective against either
Party hereto, unless in writing, signed by the Party against which such waiver, modification or amendment is asserted, and referring specifically to the provision hereof alleged to be waived, modified or amended. The failure or delay of either Party
to insist upon the other Party’s strict performance of the provisions in this Agreement or to exercise in any respect any right, power, privilege, or remedy provided for under this Agreement shall not operate as a waiver or relinquishment
thereof, nor shall any single or partial exercise of any right, power, privilege or remedy preclude other or further exercise thereof, or the exercise of any other right, power, privilege, or remedy; provided, however, that the obligations and
duties of either Party with respect to the performance of any term or condition in this Agreement shall continue in full force and effect. The execution of this Agreement by the Parties does not constitute or evidence any waiver of any right, or
remedy Cerus may have against Baxter under the Original Supply Agreement. 
 Section 12.12 Alternative Dispute
Resolution. The Parties will attempt to settle any claim or controversy arising out of this Agreement through good faith negotiations and in the spirit of mutual cooperation. Any issues that cannot be resolved will be referred to
a senior management representative from each of the Parties who has the authority to resolve the dispute. In the event such senior management representatives cannot resolve the dispute, the dispute will be submitted to binding arbitration for
resolution. Any such proceedings shall be conducted at the place of the principal office of the respondent in accordance with Commercial Arbitration Rules of the American Arbitration Association (“AAA”). Any such proceedings
shall be conducted at the place of the principal office of the respondent in accordance with the Commercial Arbitration Rules of the AAA. Any such dispute or controversy shall be arbitrated 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 31 

 
before a single arbitrator selected in accordance with the rules of the AAA. The arbitrator’s decision shall be final and binding upon the parties. The parties shall be entitled to full
discovery in any such arbitration. Each party shall bear one half of the cost of such arbitration, unless the arbitrator otherwise allocates such costs. Judgment on the award rendered by the arbitrator(s) may be entered in any court having
jurisdiction thereof. Nothing in this Section will prevent either Party from resorting to judicial process if injunctive relief from a court is necessary to prevent serious and irreparable injury to one Party or to others. 

Section 12.13 Joint and Several Liability. Fresenius Kabi’s obligations and liability under this Agreement shall be
joint and several, including without limitation, with respect to each such party’s indemnification obligations under Article 11. 

Section 12.14 Availability of Injunction. Fresenius Kabi and Cerus agree that any breach, or threatened breach, of this
Agreement by one Party could cause irreparable damage to the other Party. The Parties agree that, in the event of such breach, or threatened breach, the Parties shall have, in addition to any and all remedies of law, the right to an injunction,
specific performance as well as all other equitable relief to prevent the violation of any obligations hereunder without the necessity of any proof of actual damages or the posting of a bond or other security. The Parties further agree that any
action pursuant to this Section can and shall be brought in the state or federal courts located in Chicago, Illinois or San Francisco, California. The Parties hereby consent to the jurisdiction of such state or federal courts over such disputes and
hereby waive and agree not to raise any and all defenses to the exercise of jurisdiction by such state or federal courts, including without limitation, personal jurisdiction, improper venue and forum non conveniens. 

 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 [Signature Page to
Follow] 
  
 32 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly
authorized representatives as of the last date set forth below. 
  

			
	FRESENIUS KABI DEUTSCHLAND GMBH
		
	By:	 	 /s/ Christian Hauer

	Name:	 	Christian Hauer
	Title:	 	President, Medical Devices Division

  

			
	By:	 	 /s/ Alexander Dettmer

	Name:	 	Alexander Dettmer
	Title:	 	 CFO, Executive Vice President Finance, Procurement & HR

Medical Devices Division

  

			
	CERUS CORPORATION
		
	By:	 	 /s/ William M. Greenman

	Name:	 	William M. Greenman
	Title:	 	President and CEO

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Signature Page 

 EXHIBIT A 

Product Specifications 

Platelet Sets 
 [ * ] 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Exhibit A 

 EXHIBIT B 

Product Specifications 

Plasma Sets 
 [ * ] 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Exhibit B 

 EXHIBIT C 

Product Specifications 

RBC Sets 
 [to be added
by amendment] 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Exhibit C 

 EXHIBIT D-1 

Transfer Price 
 [ * ] 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Exhibit D 

 EXHIBIT D-2 

Cerus Transfer Pricing 

[ * ] 
  

					
	 	  	 Cerus Transfer Price
	  	 Cerus Discounted Transfer Price for [ * ]

	 [ * ]
	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]
	 [ * ]
	  	[ * ]	  	[ * ]

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Exhibit D 

 Exhibit E 

Steering Committee Members 
  

			
	 Fresenius Kabi Members
	  	 Cerus Members

	 [ * ]
	  	[ * ]

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Exhibit E 

 EXHIBIT F 

Funded Projects 
 [ * ]

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Exhibit F 

 EXHIBIT G 

[ * ] 
 [attached]

 [ * ] 

  
 AMENDED AND RESTATED
MANUFACTURING AND SUPPLY AGREEMENT (FRESENIUS KABI – CERUS) 
 [ * ] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN
OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 Exhibit G

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00255-of-00352.parquet"}]]